BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35399501)

  • 1. AZD5153, a Bivalent BRD4 Inhibitor, Suppresses Hepatocarcinogenesis by Altering BRD4 Chromosomal Landscape and Modulating the Transcriptome of HCC Cells.
    Lin CH; Kuo JC; Li D; Koenig AB; Pan A; Yan P; Bai XF; Lee RJ; Ghoshal K
    Front Cell Dev Biol; 2022; 10():853652. PubMed ID: 35399501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRD4 Inhibitor AZD5153 Suppresses the Proliferation of Colorectal Cancer Cells and Sensitizes the Anticancer Effect of PARP Inhibitor.
    Zhang P; Li R; Xiao H; Liu W; Zeng X; Xie G; Yang W; Shi L; Yin Y; Tao K
    Int J Biol Sci; 2019; 15(9):1942-1954. PubMed ID: 31523195
    [No Abstract]   [Full Text] [Related]  

  • 3. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
    Rhyasen GW; Hattersley MM; Yao Y; Dulak A; Wang W; Petteruti P; Dale IL; Boiko S; Cheung T; Zhang J; Wen S; Castriotta L; Lawson D; Collins M; Bao L; Ahdesmaki MJ; Walker G; O'Connor G; Yeh TC; Rabow AA; Dry JR; Reimer C; Lyne P; Mills GB; Fawell SE; Waring MJ; Zinda M; Clark E; Chen H
    Mol Cancer Ther; 2016 Nov; 15(11):2563-2574. PubMed ID: 27573426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AZD5153 Inhibits Prostate Cancer Cell Growth in Vitro and in Vivo.
    Shen G; Chen J; Zhou Y; Wang Z; Ma Z; Xu C; Jiang M
    Cell Physiol Biochem; 2018; 50(2):798-809. PubMed ID: 30308485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of potent and novel dual NAMPT/BRD4 inhibitors for efficient treatment of hepatocellular carcinoma.
    Yin C; Jia S; Yang X; Wu L
    Eur J Med Chem; 2024 May; 271():116444. PubMed ID: 38691889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AZD5153, a novel BRD4 inhibitor, suppresses human thyroid carcinoma cell growth in vitro and in vivo.
    Xu K; Chen D; Qian D; Zhang S; Zhang Y; Guo S; Ma Z; Wang S
    Biochem Biophys Res Commun; 2018 May; 499(3):531-537. PubMed ID: 29596834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2.
    Takimoto-Shimomura T; Tsukamoto T; Maegawa S; Fujibayashi Y; Matsumura-Kimoto Y; Mizuno Y; Chinen Y; Shimura Y; Mizutani S; Horiike S; Taniwaki M; Kobayashi T; Kuroda J
    Invest New Drugs; 2019 Apr; 37(2):210-222. PubMed ID: 29931583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRD4 Inhibition by AZD5153 Promotes Antitumor Immunity via Depolarizing M2 Macrophages.
    Li X; Fu Y; Yang B; Guo E; Wu Y; Huang J; Zhang X; Xiao R; Li K; Wang B; Hu J; Sun C; Chen G
    Front Immunol; 2020; 11():89. PubMed ID: 32184777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
    Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma.
    Sengupta D; Kannan A; Kern M; Moreno MA; Vural E; Stack B; Suen JY; Tackett AJ; Gao L
    Epigenetics; 2015; 10(6):460-6. PubMed ID: 25941994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic Targeting of
    Huang M; Zeki J; Sumarsono N; Coles GL; Taylor JS; Danzer E; Bruzoni M; Hazard FK; Lacayo NJ; Sakamoto KM; Dunn JCY; Spunt SL; Chiu B
    Cancer Res; 2020 Mar; 80(5):1024-1035. PubMed ID: 31900258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression.
    Li GQ; Guo WZ; Zhang Y; Seng JJ; Zhang HP; Ma XX; Zhang G; Li J; Yan B; Tang HW; Li SS; Wang LD; Zhang SJ
    Oncotarget; 2016 Jan; 7(3):2462-74. PubMed ID: 26575167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of CCR2 and CD180 as Robust Pharmacodynamic Tumor and Blood Biomarkers for Clinical Use with BRD4/BET Inhibitors.
    Yeh TC; O'Connor G; Petteruti P; Dulak A; Hattersley M; Barrett JC; Chen H
    Clin Cancer Res; 2017 Feb; 23(4):1025-1035. PubMed ID: 28073847
    [No Abstract]   [Full Text] [Related]  

  • 14. Co-overexpression of BRD4 and CDK7 promotes cell proliferation and predicts poor prognosis in HCC.
    Li X; Zheng C; Liu Y; Sun H; Qian Y; Fan H
    Heliyon; 2024 Jan; 10(2):e24389. PubMed ID: 38293462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. microRNA-608 inhibits human hepatocellular carcinoma cell proliferation via targeting the BET family protein BRD4.
    He L; Meng D; Zhang SH; Zhang Y; Deng Z; Kong LB
    Biochem Biophys Res Commun; 2018 Jul; 501(4):1060-1067. PubMed ID: 29777702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRD4 inhibitor GNE987 exerts anti-cancer effects by targeting super-enhancers in neuroblastoma.
    Chen YL; Li XL; Li G; Tao YF; Zhuo R; Cao HB; Jiao WY; Li ZH; Zhu ZH; Fang F; Xie Y; Liao XM; Wu D; Wang HR; Yu JJ; Jia SQ; Yang Y; Feng CX; Yang PC; Fei XD; Wang JW; Xu YY; Qian GH; Zhang ZM; Pan J
    Cell Biosci; 2022 Mar; 12(1):33. PubMed ID: 35303940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FK866-induced NAMPT inhibition activates AMPK and downregulates mTOR signaling in hepatocarcinoma cells.
    Schuster S; Penke M; Gorski T; Gebhardt R; Weiss TS; Kiess W; Garten A
    Biochem Biophys Res Commun; 2015 Mar; 458(2):334-40. PubMed ID: 25656579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRD4 promotes tumor growth and epithelial-mesenchymal transition in hepatocellular carcinoma.
    Zhang P; Dong Z; Cai J; Zhang C; Shen Z; Ke A; Gao D; Fan J; Shi G
    Int J Immunopathol Pharmacol; 2015 Mar; 28(1):36-44. PubMed ID: 25816404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-766-5p Targets Super-Enhancers by Downregulating CBP and BRD4.
    Gen Y; Muramatsu T; Inoue J; Inazawa J
    Cancer Res; 2021 Oct; 81(20):5190-5201. PubMed ID: 34353856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study.
    Jung M; Kim S; Lee JK; Yoon SO; Park HS; Hong SW; Park WS; Kim JE; Kim J; Keam B; Kim HJ; Kang HJ; Kim DW; Jung KC; Kim YT; Heo DS; Kim TM; Jeon YK
    Oncologist; 2019 Aug; 24(8):e740-e748. PubMed ID: 30696721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.